Cytovene (ganciclovir) / Roche 
Welcome,         Profile    Billing    Logout  
 268 Diseases   30 Trials   30 Trials   2139 News 


«12...7891011121314151617...3536»
  • ||||||||||  Cytovene (ganciclovir) / Roche
    MENINGOENCEPHALITIS AND MYOCARDITIS: SEVERE PRESENTATION FORMS OF HUMAN HERPES VÍRUS-6 INFECTION IN A HEALTHY TODDLER () -  May 19, 2022 - Abstract #ESPID2022ESPID_997;    
    Empiric high-dose ceftriaxone and acyclovir were prescribed...Due to the severity of the clinical picture, antiviral treatment was replaced by ganciclovir on the second day of hospitalization, after the detection of herpesvirus-6 in the molecular panel...Learning Points/ HHV-6 can cause encephalitis, accompanied or not by meningitis, with the ability to generate brain epileptiform activities in immunocompetent individuals. Encephalitis and myocarditis may be caused by primary infection or reactivation, being most observed in organ transplant recipients or AIDS.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
    BALANCE ISSUES IN CONGENITAL CYTOMEGALOVIRUS: A CASE SERIES OF PATIENTS FROM A SINGLE UK CENTRE () -  May 19, 2022 - Abstract #ESPID2022ESPID_960;    
    1 has ADHD with anxiety and behavioural difficulties, 1 has severe behavioural difficulties and 1 has cerebral visual impairment Learning Points/ This case series highlights the importance of follow up for babies with cCMV and demonstrates that vestibular/balance problems are found in one third. A collaborative national approach is essential to determine the natural progression of this disease and the efficacy of early antiviral treatment on all long-term sequelae.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Cellular Senescence and the Associated Secretome Contribute to Age-Related Vascular Dysfunction. (Pubmed Central) -  May 14, 2022   
    Fisetin supplementation may be a novel strategy to target excess cellular senescence and thereby reduce mito ROS to improve NO-mediated endothelial function with aging. The circulating SASP factors may be a mechanism by which cellular senescence induces age-related vascular dysfunction, and as such, these processes represent novel therapeutic targets.
  • ||||||||||  Cytovene (ganciclovir) / Roche, brivudine (RP 101) / RESprotect, RedHill, SciClone
    ASSESSING GENOMIC SAFETY OF ANTIVIRAL NUCLEOSIDE ANALOGS IN HEMATOPOIETIC STEM CELLS () -  May 13, 2022 - Abstract #EHA2022EHA_2502;    
    Indeed, we have shown that treatment with the antiviral NA ganciclovir (GCV) after stem cell transplantation induces an increased mutation burden in the hematopoietic stem and progenitor cells (HSPCs) of pediatric leukemia patients...Of note, the thymidine analog brivudine showed the highest increase in single base substitutions, which were characterized by a T>C signature, depleted for flanking cytosines...Conclusion Many compounds of the NA class currently prescribed for the treatment of viral infections are mutagenic to healthy cells. This calls for more thorough screening of these drugs, incorporation of information on mutagenicity to healthy cells in drug safety guidelines and patient surveillance over time.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
    Journal:  Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection. (Pubmed Central) -  May 9, 2022   
    Since these early days, ganciclovir, and subsequently its prodrug valganciclovir, have become the standard of care for the treatment of congenital cytomegalovirus infection. The following commentary defines the need and progress in the development of therapy.
  • ||||||||||  Cytovene (ganciclovir) / Roche, Livtencity (maribavir) / Takeda, GSK
    Preclinical, Journal:  Impact of new cyclooxygenase 2 inhibitors on human cytomegalovirus replication in vitro. (Pubmed Central) -  May 6, 2022   
    Azathioprine aided in discontinuing prednisolone and stabilizing the patient's condition for approximately four years. These results provide a promising search path for potential bitherapies against HCMV.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Systemic Gene Therapy for Brain Malignancy Using Blood-Brain-Barrier-Penetrant AAV Vectors (Poster Board Number: M-225; Hall D) -  May 6, 2022 - Abstract #ASGCT2022ASGCT_1488;    
    Future studies would examine the translational potential of combinatorial treatment of AAV.CPP.16-HSV-TK1 and PD-L1 immunotherapy. Thus, our studies so far suggest the feasibility and prospect of developing AAV-based systemic gene therapy for combatting highly malignant brain tumors.
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Journal:  Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients. (Pubmed Central) -  Apr 30, 2022   
    Our study emphasizes that the clinical follow-up in combination with genotypic and phenotypic studies is essential for the assessment and optimization of patients experiencing HCMV relapses or not responding to antiviral therapy. This information may be important for other researchers and clinicians working in the field to improve the care of transplant patients since drug-resistant CMV infections are an important emerging problem even with the new antiviral development.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
    Journal:  Cytomegalovirus colitis in a child with leukemia: a case report. (Pubmed Central) -  Apr 29, 2022   
    Consequently, he responded dramatically to treatment with ganciclovir. Although cytomegalovirus colitis is rare, a few case reports suggest cytomegalovirus as a possible cause of colitis in children with leukemia, which can be fatal and should be considered as a differential diagnosis.
  • ||||||||||  FML, FML Forte (fluorometholone ophthalmic suspension) / AbbVie, Cytovene (ganciclovir) / Roche
    Review, Journal:  Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis. (Pubmed Central) -  Apr 22, 2022   
    The currently available evidence is insufficient to determine whether any of the evaluated interventions confers an advantage over steroids or artificial tears with respect to virus eradication or its spread to initially uninvolved fellow eyes. Future updates of this review should provide evidence of high-level certainty from trials with larger sample sizes, enrollment of participants with similar durations of signs and symptoms, and validated methods to assess short- and long-term outcomes.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy. (Pubmed Central) -  Apr 9, 2022   
    Unexpectedly, post-mitotic neurons with ubiquitous SR39h expression were killed by ganciclovir, but were spared when SR39h was expressed under the control of the cell cycle-dependent Ki67 promoter...We tested three nucleoside analogs in vivo: at concentrations of 40 mg/kg/day, PCV and GCV prevented tumor formation, while acyclovir (ACV) did not...In this setting, PCV and GCV are efficient inducers of cell death. Because of its low toxicity, PCV might become a preferred alternative to GCV.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Role of p16 expressing cells in formation and function of T cell memory with age (Exhibit Hall; P1018) -  Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_2528;    
    p16 is commonly upregulated in senescent cells so this model allows us to detect senescent cells via luciferase activity, RFP expression, and selectively delete those cells by treating with ganciclovir (GCV)...Conversely, during primary infection, deletion of p16 expressing cells induced a more youthful response in aged mice. This suggests that targeting senescent cells is a double-edged sword that may potentiate primary responses to infection while severely limiting the ability to form durable and protective memory.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Safety, efficacy and delivery of multiple nucleoside analogs via drug encapsulated carbon (DECON) based sustained drug release platform. (Pubmed Central) -  Apr 6, 2022   
    Similarly we also demonstrate that nucleoside analog loaded carbons termed DECON are effective at very low concentrations in treating active viral infection of human corneal epithelial cells. In this study, using a variety of techniques to evaluate corneal dryness, nerve sensitivity, intraocular pressure, corneal thickness, and somatic inflammation, we report that DECON is well tolerated after administration three times daily over the course of four weeks.
  • ||||||||||  Vistide (cidofovir) / Gilead, Sovaldi (sofosbuvir) / Gilead
    Journal:  A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951-2021). (Pubmed Central) -  Apr 5, 2022   
    In this study, using a variety of techniques to evaluate corneal dryness, nerve sensitivity, intraocular pressure, corneal thickness, and somatic inflammation, we report that DECON is well tolerated after administration three times daily over the course of four weeks. John Charles Martin should be remembered as a visionary medicinal chemist who was involved in the coinvention, development, or management of many FDA-approved antiviral drugs such as ganciclovir, stavudine, didanosine, cidofovir, oseltamivir, adefovir dipivoxil, tenofovir disoproxil fumarate, tenofovir alafenamide, sofosbuvir, and remdesivir.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Retrospective data, Journal:  COVID-19 associated EBV reactivation and effects of ganciclovir treatment. (Pubmed Central) -  Apr 5, 2022   
    A high proportion of COVID-19 patients had EBV reactivation that may be associated with an increased risk of death. Whether treatment with ganciclovir may decrease the mortality of COVID-19 patients complicated with EBV reactivation warrants to be addressed in a placebo-controlled randomized trial in the future.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe
    Journal:  Risk Assessment of Neutropenia during Low-Dose Valganciclovir Prophylaxis for Heart Transplant Recipients. (Pubmed Central) -  Apr 5, 2022   
    Meanwhile, the cumulative dose of mycophenolate mofetil was significantly higher in the prophylaxis group than in the no prophylaxis group (p = 0.018); the daily maintenance dose and regularly measured area under the concentration-time curve (AUC) of mycophenolic acid did not significantly differ between groups. In conclusion, the risk of developing neutropenia was higher in HTRs receiving low-dose VGCV prophylaxis than it was in those not receiving prophylaxis, probably not attributed to dosing period and cumulative dose of VGCV until the onset of neutropenia.
  • ||||||||||  Cytovene (ganciclovir) / Roche
    Journal:  Selective Depletion of Adult GFAP-Expressing Tanycytes Leads to Hypogonadotropic Hypogonadism in Males. (Pubmed Central) -  Apr 5, 2022   
    To explore the role of these hypothalamic GFAP-positive tanycytes, we used transgenic mice expressing herpes simplex virus thymidine kinase (HSV-Tk) under the control of the mouse Gfap promoter and a 4-week intracerebroventricular infusion of the antiviral agent ganciclovir (GCV) which kills dividing cells expressing Tk...Our results also show that the selective depletion of GFAP-expressing tanycytes leads to a sharp decrease in the number of gonadotropin-releasing hormone (GnRH)-immunoreactive neurons and a blunted LH secretion. Overall, our data show that GFAP-expressing tanycytes play a central role in the regulation of male reproductive function.